This is an attempt to explain the MiRus pivot to my ortho/spine readers. It's hard to get your head around going from $15M sales run rate to a $4B exit.
If I am honest, I have never been a fan of MiRus trying to break into the spine markets with the new proprietary alloy MoRe® (Molybdenum-Rhenium).
Sure, MoRe is 2-3 times stronger than Ti alloys, twice as stiff and has better fatigue life, but that's not what the spine customer needs in 2026. Today, they need throughput. Read The Thoughput Question here - https://orthostreams.com/2026/03/the-throughput-question-are-you-an-accelerator-or-a-speed-bump/
I interviewed Dr. Jay Yadav, MiRus founder, for OrthoStreams back in 2019 - link is here - https://www.linkedin.com/pulse/6-questions-dr-jay-yadav-founder-mirus-who-bringing-new-tiger-buford/
Jay was already a successful entrepreneurial cardio medtech founder after his big exit in 2014 at CardioMems.
However, he became distracted with spine and spent years trying to compete in the noisy spine market with a new alloy with marginal benefits and poor sales traction. Estimates of MiRus (private company) sales are $10-15M annual spine sales.
That all changed this week.
MiRus just pivote...
